Granulomatosis with Polyangiitis News and Research

RSS

Investigating the efficacy and safety of existing drugs in patients with rare immune diseases

This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.

23 Apr 2024

Researchers identify new therapeutic for patients with a rare autoimmune disease EGPA

An international team, including researchers from McMaster University and St. Joseph's Healthcare Hamilton, has identified a new therapeutic for patients with a rare autoimmune disease called eosinophilic granulomatosis with polyangiitis (EGPA).

24 Feb 2024

Three new guidelines released for treatment and management of systemic vasculitis

The American College of Rheumatology, in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis.

9 Jul 2021

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX), a prophylactic therapy to help prevent pneumocystis pneumonia, are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies.

6 Nov 2020

FDA approves first drug for patients with hypereosinophilic syndrome in nearly 14 years

Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

25 Sep 2020

The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease released

The American College of Rheumatology and the European League Against Rheumatism released the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease. It is the first criteria developed specifically for this recently recognized disease.

4 Dec 2019

Researchers reveal promising biomarker for vascular disease relapse

Researchers at Okayama University report in the journal Arthritis & Rheumatology that monitoring a particular antigen can be used for predicting relapse of the vascular disease AAV.

28 Feb 2019

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

FDA-approved drug improves clinical outcomes among patients with rare immunologic disease

Adding the injectable drug mepolizumab to standard treatment for eosinophilic granulomatosis with polyangiitis (EGPA), a rare immunologic disease, significantly improved clinical outcomes among participants in an advanced clinical trial, scientists report.

18 May 2017

Two new studies on eosinophilic granulomatosis with polyangiitis selected by Vasculitis Foundation

The Vasculitis Foundation is pleased to announce it has selected two new research studies on eosinophilic granulomatosis with polyangiitis (EGPA) /Churg Strauss for funding in the amount of $98,000.

14 Aug 2015

New study launched to find impact of vasculitis on employment, income

The Vasculitis Patient-Powered Research Network and the Vasculitis Clinical Research Consortium launched a study entitled "Impact of vasculitis on employment and income" or "VascWork." The purpose of this study is to learn about the impact of vasculitis on employment and income in patients with different systemic vasculitides.

12 Aug 2015

NICE approves MabThera for treating severe forms of GPA and MPA

Today the National Institute for Health and Care Excellence has approved the use of MabThera for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the breaking down of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death.

24 Jan 2014

Vasculitis damage swift, accumulating

Study findings reveal the significant burden of disease among patients with antineutrophil-cytoplasm antibody associated vasculitis, with many individuals showing irreversible damage shortly after diagnosis.

22 Nov 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Powerful new option for treating vasculitis

In a study published in the New England Journal of Medicine, a research consortium that includes the University of Alabama at Birmingham (UAB) has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.

27 Aug 2013

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis, or inflammation of the blood vessels, a study has found.

1 Aug 2013

ANCA-associated vasculitis not a single clinical entity

Study findings show distinct subtypes of antineutrophil cytoplasmic antibody-associated vasculitis, distinguished by the target of autoantigen reactivity.

25 Jul 2012

HHS scientists to share recent rheumatology findings at 75th ACR annual meeting

Hospital for Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis and related conditions are traveling from New York City to Chicago this week to share their recent findings at the 75th Annual Scientific Meeting of the American College of Rheumatology.

7 Nov 2011

Psychological stress can trigger flares of vasculitis

In patients with a devastating form of vasculitis who are in remission, stress can be associated with a greater likelihood of the disease flaring, according to a new study by investigators at Hospital for Special Surgery.

6 Nov 2011

Roche Canada grants Vasculitis and Scleroderma Fellowship

Roche Canada announced today its support of a Vasculitis and Scleroderma Fellowship through the Division of Rheumatology at the University of British Columbia (UBC). Dr. Ada Man, a recent graduate of the UBC rheumatology residency program, is the recipient of the one-year Fellowship.

23 Aug 2011